Neurocardiogenic syncope: latest pharmacological therapies

被引:9
|
作者
Chen, LY [1 ]
Shen, WK [1 ]
机构
[1] Mayo Clin, Coll Med, Div Cardiovasc Dis & Int Med, Rochester, MN 55905 USA
关键词
beta-blockers; midodrine; neurocardiogenic syncope;
D O I
10.1517/14656566.7.9.1151
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neurocardiogenic syncope is a neurally mediated disorder and is a common cause of syncope. The goal of treatment is to prevent recurrences with the aim of improving quality of life and reducing morbidity. Reassurance, in some cases, may suffice. In others, augmenting central blood volume by increasing fluid and/or salt intake is effective. The role of non-pharmacological physical manoeuvres is increasingly recognised, given the increasing clinical trial data supporting their efficacy. This review summarises the clinical evidence for a variety of pharmacological agents. Of these, midodrine appears to have yielded the most consistent favourable outcome. its use, however, should be reserved for patients with recurrent and refractory syncope.
引用
收藏
页码:1151 / 1162
页数:12
相关论文
共 50 条
  • [21] Neurocardiogenic syncope in long–QT syndrome is not necessarily benign
    Jørgen K. Kanters
    Poul Erik Bloch Thomsen
    Michael Christiansen
    Egon Toft
    Clinical Research in Cardiology, 2006, 95 : 349 - 350
  • [22] Neurocardiogenic syncope in children: Current concepts in diagnosis and management
    Martial M. Massin
    Pediatric Drugs, 2003, 5 (5) : 327 - 334
  • [23] Neurocardiogenic syncope in a 10-year-old boy
    Meyer, K
    Galler, A
    Lietz, R
    Siekmeyer, W
    PEDIATRIC CARDIOLOGY, 2001, 22 (05) : 415 - 416
  • [24] Basic autonomic nervous function in patients with neurocardiogenic syncope
    Saito, Fumio
    Imai, Shinobu
    Tanaka, Nobuyuki
    Tanaka, Hideyuki
    Suzuki, Kazutaka
    Takase, Hidehito
    Aoyama, Hiroshi
    Matsudaira, Kagari
    Ebuchi, Tomonori
    Akamine, Yasuyuki
    Takahashi, Naoyuki
    Sugino, Keiichi
    Kanmatsuse, Katsuo
    Yagi, Hiroshi
    Kushiro, Toshio
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2007, 29 (03) : 165 - 173
  • [25] Tilt training program for the prevention of neurocardiogenic syncope in the elderly
    Abe, H
    Kohshi, K
    Nakashima, Y
    PHYSICAL FITNESS AND HEALTH PROMOTION IN ACTIVE AGING, 2001, 17 : 149 - 155
  • [26] Atrial Electromechanical Conduction Delay in Patients with Neurocardiogenic Syncope
    Sucu, Murat
    Ercan, Suleyman
    Uku, Okkes
    Davutoglu, Vedat
    Altunbas, Gokhan
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2014, 37 (05): : 597 - 602
  • [27] Home orthostatic self-training in neurocardiogenic syncope
    Abe, H
    Kohshi, K
    Nakashima, Y
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2005, 28 : S246 - S248
  • [28] Diagnosing neurocardiogenic syncope [Diagnostik der neurokardiogenen synkope]
    Hoffmann N.
    Steffen H.-M.
    Herzschrittmachertherapie und Elektrophysiologie, 2002, 13 (2): : 72 - 78
  • [29] Driving safety among patients with neurocardiogenic (Vasovagal) syncope
    Bhatia, A
    Dhala, A
    Blanck, Z
    Deshpande, S
    Akhtar, M
    Sra, J
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1999, 22 (11): : 1576 - 1580
  • [30] Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications
    Yu, JCL
    Sung, RJ
    CARDIOVASCULAR DRUGS AND THERAPY, 1997, 10 (06) : 687 - 692